Watch VTGN. Know when insiders buy.
One email the day a filing lands. Free.
VTGN
Vistagen Therapeutics, Inc.
0.28
+0.00 +0.00%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
30
FLAG · shorts 30
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$67.6MNET CASH $16.9M52W 0.23 – 4.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | — | — | — | −$13.3M | −$13M | — | -0.30 | −$14.7M | — | — | Aug 14 |
| Q4 2026 · Mar 31derived | — | — | — | −$16.7M | −$16.3M | — | -0.37 | −$16.2M | — | — | Jun 15 |
| Q3 2026 · Dec 31 | — | — | — | −$19.5M | −$18.9M | — | -0.45 | −$17.6M | — | — | Feb 12 |
| Q2 2026 · Sep 30 | — | — | — | −$20.1M | −$19.4M | — | -0.54 | −$13.8M | — | — | Feb 12 |
| Q1 2026 · Jun 30 | — | — | — | −$15.8M | −$15.1M | — | -0.47 | −$18.8M | — | — | Aug 14 |
| Q4 2025 · Mar 31derived | — | — | — | −$14.5M | −$13.6M | — | -0.44 | −$10.1M | — | — | Jun 15 |
| Q3 2025 · Dec 31 | — | — | — | −$15.1M | −$14.1M | — | -0.46 | −$10.3M | — | — | Feb 12 |
| Q2 2025 · Sep 30 | — | — | — | −$14.2M | −$13M | — | -0.42 | −$10.9M | — | — | Feb 12 |
| Q1 2025 · Jun 30 | — | — | — | −$12.1M | −$10.7M | — | -0.35 | −$10.9M | — | — | Feb 12 |
| Q4 2024 · Mar 31derived | — | — | — | −$11.4M | −$9.5M | — | -0.25 | −$7M | — | — | Jun 17 |
| Q3 2024 · Dec 31 | — | — | — | −$7.9M | −$6.3M | — | -0.22 | −$4.7M | — | — | Feb 13 |
| Q2 2024 · Sep 30 | — | — | — | −$6.8M | −$6.6M | — | -0.66 | −$6.2M | — | — | Feb 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | — | — | −$72.1M | −$69.7M | — | -1.83 | −$66.4M | — | — | — | — |
| FY2025 · to Mar 31 | — | — | −$56M | −$51.4M | — | -1.67 | −$42.1M | — | — | — | — |
| FY2024 · to Mar 31 | — | — | −$33M | −$29.4M | — | -1.52 | −$25.8M | $0 | −$25.8M | — | — |
| FY2023 · to Mar 31 | −$227K | — | −$59.3M | −$59.2M | 26100.4% | -8.51 | −$49.7M | $528K | −$50.2M | — | — |
| FY2022 · to Mar 31 | $1.1M | — | −$47.8M | −$47.8M | -4306.8% | -7.38 | −$45.3M | $200K | −$45.5M | — | — |
| FY2021 · to Mar 31 | $1.1M | — | −$17.9M | −$17.9M | -1646.1% | -0.49 | −$12.1M | $275K | −$12.3M | — | — |
Every number comes from Vistagen Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.